Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • 2-Gene Colorectal Cancer Recurrence Test: Clinical trial data

    Clinical Genomics Pty. Ltd., North Ryde, Australia Product: 2-Gene Colorectal Cancer Recurrence Test Business: Diagnostic Molecular target: NA Description: Blood test that detects tumor-specific methylated cytosolic …

    Published on 2/1/2016
  • Birinapant: Phase II discontinued

    TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Birinapant (formerly TL32711) Business: Cancer Molecular target: Inhibitor of apoptosis (IAP) Description: Small molecule peptidomimetic of diablo …

    Published on 2/1/2016
  • CaCP29: Phase IIa data

    InflaRx GmbH, Jena, Germany Product: CaCP29, IFX-1 Business: Infectious Molecular target: Complement 5a (C5a) Description: mAb against complement 5a (C5a) Indication: Treat septic organ dysfunction Endpoint: Safety, …

    Published on 2/1/2016
  • CAT-1004: Phase I/II data

    Catabasis Pharmaceuticals Inc. (NASDAQ:CATB), Cambridge, Mass. Product: CAT-1004 Business: Musculoskeletal Molecular target: Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB) (NFKB1) (p105) (…

    Published on 2/1/2016
  • Demcizumab: Additional Phase Ib data

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Demcizumab (OMP-21M18) Business: Cancer Molecular target: Delta-like 4 (DLL4) Description: Humanized IgG2 mAb against delta-like 4 (DLL4) …

    Published on 2/1/2016
  • DKN-01: Phase I data

    Leap Therapeutics Inc., Cambridge, Mass. Product: DKN-01 Business: Cancer Molecular target: Dickkopf homolog 1 (DKK1) Description: Humanized IgG4 mAb against dickkopf homolog 1 (DKK1) Indication: Treat esophageal cancer…

    Published on 2/1/2016
  • FPA144: Preliminary Phase I data

    Five Prime Therapeutics Inc. (NASDAQ:FPRX), South San Francisco, Calif. Product: FPA144 Business: Cancer Molecular target: Keratinocyte growth factor (KGF) receptor b isoform (FGFR2b) Description: Humanized mAb against …

    Published on 2/1/2016
  • GLPG1205: Development discontinued

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium Product: GLPG1205 Business: Autoimmune Molecular target: G protein-coupled receptor 84 (GPR84) Description: G protein-coupled receptor 84 (GPR84) inhibitor …

    Published on 2/1/2016
  • Halofuginone: Phase Ib/IIa suspended enrollment

    Akashi Therapeutics Inc., Cambridge, Mass. Gruenenthal Group, Aachen, Germany Product: Halofuginone (HT-100) Business: Musculoskeletal Molecular target: Glutamyl-prolyl-tRNA synthetase (EPRS) Description: Oral delayed-…

    Published on 2/1/2016
  • Indoximod: Phase Ib/II data

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Product: Indoximod (1-MT) (NLG8189) 1-methyl-D-tryptophan Business: Cancer Molecular target: Indoleamine 2,3-dioxygenase (INDO) (IDO) Description: Indoleamine 2,3-…

    Published on 2/1/2016
  • IX-01: Phase IIa data

    Ixchelsis Ltd., Sandwich, U.K. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: IX-01 Business: Genitourinary Molecular target: Oxytocin receptor (OXTR) Description: Oxytocin receptor (OXTR) antagonist Indication: Treat …

    Published on 2/1/2016
  • Jakafi: Phase II data

    Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Jakafi ( Jakavi - EU) ruxolitinib (INCB18424) Business: Cancer Molecular target: Janus kinase-1 (JAK-1); Janus …

    Published on 2/1/2016
  • Napabucasin: Phase Ib data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Napabucasin (BBI608) Business: Cancer Molecular target: Signal transducer and activator of transcription 3 (STAT3) Description: Small molecule …

    Published on 2/1/2016
  • Napabucasin: Phase Ib data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Napabucasin (BBI608) Business: Cancer Molecular target: Signal transducer and activator of transcription 3 (STAT3) Description: Small molecule …

    Published on 2/1/2016
  • Napabucasin: Phase Ib/II data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Napabucasin (BBI608) Business: Cancer Molecular target: Signal transducer and activator of transcription 3 (STAT3) Description: Small molecule …

    Published on 2/1/2016
  • Opdivo nivolumab: Phase III data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Opdivo nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell …

    Published on 2/1/2016
  • Orkambi ivacaftor/lumacaftor: Phase III data

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Product: Orkambi ivacaftor/lumacaftor, ivacaftor/VX-809 Business: Pulmonary Molecular target: Cystic fibrosis transmembrane conductance regulator (CFTR) …

    Published on 2/1/2016
  • ProCervix: Phase II data

    Genticel S.A. (Euronext:GTCL), Labege, France Product: ProCervix (GTL001) Business: Cancer Molecular target: Human papillomavirus (HPV) antigens Description: Bivalent therapeutic cancer vaccine against HPV types 16 and …

    Published on 2/1/2016
  • RDX022: Phase I data

    Ardelyx Inc. (NASDAQ:ARDX), Fremont, Calif. Product: RDX022 Business: Endocrine/Metabolic Molecular target: NA Description: Non-absorbed, potassium-binding polymer based on polystyrene sulfonate Indication: Treat …

    Published on 2/1/2016
  • SGN-LIV1A: Interim Phase I data

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Product: SGN-LIV1A (formerly Anti-LIV-1 ADC) Business: Cancer Molecular target: Solute carrier family 39 zinc transporter member 6 (SLC39A6) (LIV-1) (ZIP6) Description…

    Published on 2/1/2016
  • Suberohydroxamic acid phenyl ester: Interim Phase II data

    TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Product: Suberohydroxamic acid phenyl ester (SHAPE) (formerly SHP-141) Business: Cancer Molecular target: Histone deacetylase (HDAC) Description: Topical gel …

    Published on 2/1/2016
  • Tarextumab: Phase Ib/II data

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Tarextumab (Anti-Notch2/3) (OMP-59R5) Business: Cancer Molecular target: Notch 2 (NOTCH2); Notch 3 (NOTCH3) Description: Human HuCAL mAb that …

    Published on 2/1/2016
  • Vesigenurtacel-L: Phase I/II data

    Heat Biologics Inc. (NASDAQ:HTBX), Durham, N.C. Product: Vesigenurtacel-L (HS-410) Business: Cancer Molecular target: Heat shock 90 kDa protein beta 1 (Hsp90B1) (GP96) (GRP94) Description: Bladder cancer cell line …

    Published on 2/1/2016
  • ALKS 5461: Phase III data

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 5461 Business: Neurology Molecular target: Mu opioid receptor (MOR) (OPRM1); Kappa opioid receptor (KOR) (OPRK1) Description: Combination of samidorphan (ALKS 33…

    Published on 1/25/2016
  • ALKS 5461: Phase III data

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 5461 Business: Neurology Molecular target: Mu opioid receptor (MOR) (OPRM1); Kappa opioid receptor (KOR) (OPRK1) Description: Combination of samidorphan (ALKS 33…

    Published on 1/25/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993